よむ、つかう、まなぶ。
【参考資料２－２】抗微生物薬適正使用の手引き 第四版（案）医科・入院編 (42 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
医科・入院編
1
2
36. Thom KA, et al. Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in
Hospitalized Patients. Clin Infect Dis. 2019. 68(9):1581–1584.
3
37. Eur Respir J 2019; 54: 1900057.
4
38. Crit Care 2024; 28:10.
5
6
39. Tamma PD, et al. Association of Adverse Events With Antibiotic Use in Hospitalized
Patients. JAMA Intern Med. 2017. 177(9):1308-1315.
7
8
9
40. Dantes R, et al. Association Between Outpatient Antibiotic Prescribing Practices and
Community-Associated Clostridium difficile Infection. Open Forum Infect Dis. 2015.
2(3):ofv113.
10
11
12
13
41. Ho C-Y, et al. Antimicrobial escalation is not beneficial for Gram-negative bacteremia in
adults who remained critically ill after appropriate empirical therapy. Journal of infection
and chemotherapy: official journal of the Japan Society of Chemotherapy. 2020.
26(9):933-940.
14
15
42. Roger P-M, et al. Risk Factors for Unnecessary Antibiotic Therapy: A Major Role for
Clinical Management. Clin Infect Dis. 2019. 69(3):466-472.
16
17
43. Baggio D, et al. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021.
44(5):161-164.
18
19
44. Bassetti M, et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units:
Results from EUCANDICU Study. Infect Dis Ther. 2022. 11(2):827-840.
20
21
22
23
45. Averbuch D, et al. European guidelines for empirical antibacterial therapy for febrile
neutropenic patients in the era of growing resistance: summary of the 2011 4th
European Conference on Infections in Leukemia. Haematologica. 2013. 98(12):18261835.
24
25
26
46. Ly WJ, et al. Evaluation of early de-escalation of empiric antimicrobial therapy in acute
leukemia patients with febrile neutropenia at a large academic medical center.J Oncol
Pharm Pract. 2023. 29(2):305-310.
27
28
29
47. Petteys MM, et al. Antimicrobial de-escalation in adult hematopoietic cell transplantation
recipients with febrile neutropenia of unknown origin. J Oncol Pharm Pract. 2020.
26(3):632-640.
30
31
48. Ohji G, et al. Is de-escalation of antimicrobials effective? A systematic review and metaanalysis. Int J Infect Dis. 2016 Aug;49:71-79.
32
33
34
49. Garnacho-Montero J, et al. De-escalation of empirical therapy is associated with lower
mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014.
40(1):32-40.
35
36
50. Guo Y, et al. De-escalation of empiric antibiotics in patients with severe sepsis or septic
shock: A meta-analysis. Heart Lung. 2016. 45(5):454-459.
37
38
39
40
51. Routsi C, et al. De-escalation of antimicrobial therapy in ICU settings with high
prevalence of multidrug-resistant bacteria: a multicentre prospective observational
cohort study in patients with sepsis or septic shock. J Antimicrob Chemother. 2020.
75(12):3665-3674.
41
42
52. Lakbar I, et al. Antimicrobial De-Escalation in the ICU: From Recommendations to Level
of Evidence. Adv Ther. 2020. 37(7):3083-3096.
43
44
45
53. Lin J, et al. De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients
with Candidemia. International journal of infectious diseases. Int J Infect Dis. 2022.
121:69-74.
42
第四版
医科・入院編
1
2
36. Thom KA, et al. Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in
Hospitalized Patients. Clin Infect Dis. 2019. 68(9):1581–1584.
3
37. Eur Respir J 2019; 54: 1900057.
4
38. Crit Care 2024; 28:10.
5
6
39. Tamma PD, et al. Association of Adverse Events With Antibiotic Use in Hospitalized
Patients. JAMA Intern Med. 2017. 177(9):1308-1315.
7
8
9
40. Dantes R, et al. Association Between Outpatient Antibiotic Prescribing Practices and
Community-Associated Clostridium difficile Infection. Open Forum Infect Dis. 2015.
2(3):ofv113.
10
11
12
13
41. Ho C-Y, et al. Antimicrobial escalation is not beneficial for Gram-negative bacteremia in
adults who remained critically ill after appropriate empirical therapy. Journal of infection
and chemotherapy: official journal of the Japan Society of Chemotherapy. 2020.
26(9):933-940.
14
15
42. Roger P-M, et al. Risk Factors for Unnecessary Antibiotic Therapy: A Major Role for
Clinical Management. Clin Infect Dis. 2019. 69(3):466-472.
16
17
43. Baggio D, et al. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021.
44(5):161-164.
18
19
44. Bassetti M, et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units:
Results from EUCANDICU Study. Infect Dis Ther. 2022. 11(2):827-840.
20
21
22
23
45. Averbuch D, et al. European guidelines for empirical antibacterial therapy for febrile
neutropenic patients in the era of growing resistance: summary of the 2011 4th
European Conference on Infections in Leukemia. Haematologica. 2013. 98(12):18261835.
24
25
26
46. Ly WJ, et al. Evaluation of early de-escalation of empiric antimicrobial therapy in acute
leukemia patients with febrile neutropenia at a large academic medical center.J Oncol
Pharm Pract. 2023. 29(2):305-310.
27
28
29
47. Petteys MM, et al. Antimicrobial de-escalation in adult hematopoietic cell transplantation
recipients with febrile neutropenia of unknown origin. J Oncol Pharm Pract. 2020.
26(3):632-640.
30
31
48. Ohji G, et al. Is de-escalation of antimicrobials effective? A systematic review and metaanalysis. Int J Infect Dis. 2016 Aug;49:71-79.
32
33
34
49. Garnacho-Montero J, et al. De-escalation of empirical therapy is associated with lower
mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014.
40(1):32-40.
35
36
50. Guo Y, et al. De-escalation of empiric antibiotics in patients with severe sepsis or septic
shock: A meta-analysis. Heart Lung. 2016. 45(5):454-459.
37
38
39
40
51. Routsi C, et al. De-escalation of antimicrobial therapy in ICU settings with high
prevalence of multidrug-resistant bacteria: a multicentre prospective observational
cohort study in patients with sepsis or septic shock. J Antimicrob Chemother. 2020.
75(12):3665-3674.
41
42
52. Lakbar I, et al. Antimicrobial De-Escalation in the ICU: From Recommendations to Level
of Evidence. Adv Ther. 2020. 37(7):3083-3096.
43
44
45
53. Lin J, et al. De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients
with Candidemia. International journal of infectious diseases. Int J Infect Dis. 2022.
121:69-74.
42